We are live on
!
Find out more
HMC
Harvard Management Company Portfolio holdings
AUM
$1.82B
1-Year Est. Return
26.23%
This Fund
S&P 500
This Quarter
Est. Return
-6.06%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$1.79B
AUM Growth
-$53.7M
(-2.9%)
Cap. Flow
+$77.8M
Cap. Flow
% of AUM
4.35%
Top 10 Holdings %
Top 10 Hldgs %
81.39%
Holding
42
New
12
Increased
7
Reduced
8
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intercontinental Exchange
ICE
|
+$234M |
| 2 |
Adobe
ADBE
|
+$152M |
| 3 |
Palo Alto Networks
PANW
|
+$61.9M |
| 4 |
PureCycle Technologies
PCT
|
+$37.4M |
| 5 |
Unity
U
|
+$23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$189M |
| 2 |
Salesforce
CRM
|
+$170M |
| 3 |
Microsoft
MSFT
|
+$130M |
| 4 |
NCNA
NuCana
NCNA
|
+$3.84M |
| 5 |
FSDC
FS Development Corp. Class A Common Stock
FSDC
|
+$2.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.96% |
| 2 | Technology | 21.24% |
| 3 | Financials | 12.87% |
| 4 | Communication Services | 7.46% |
| 5 | Consumer Discretionary | 6.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Royalty Pharma
RPRX
$26.1B
| $467M | 26.11% |
10,714,284
-3,976,496
| -27% | -$189M |
|
|
2
Intercontinental Exchange
ICE
$82.4B
| $230M | 12.87% |
+2,062,444
| New | +$234M |
|
|
3
Adobe
ADBE
$89.5B
| $155M | 8.66% |
+326,100
| New | +$152M |
|
4
AbCellera Biologics
ABCL
$1.62B
| $139M | 7.79% |
4,105,095
| – | – |
|
5
Meta Platforms (Facebook)
META
$1.51T
| $121M | 6.74% |
409,695
+3,155
| +0.8% | +$850K |
|
|
6
Palo Alto Networks
PANW
$264B
| $110M | 6.13% |
2,045,400
+1,042,188
| +104% | +$61.9M |
|
|
LNW
7
DELISTED
Light & Wonder
LNW
| $103M | 5.76% |
2,678,571
| – | – |
|
|
8
Microsoft
MSFT
$2.84T
| $61.7M | 3.45% |
261,792
-559,270
| -68% | -$130M |
|
|
9
Salesforce
CRM
$134B
| $34.9M | 1.95% |
164,622
-762,919
| -82% | -$170M |
|
10
Invesco QQQ Trust
QQQ
$455B
| $34.4M | 1.92% |
107,944
-4,821
| -4% | -$1.54M |
|
|
11
PureCycle Technologies
PCT
$1.17B
| $32.5M | 1.82% |
+1,276,267
| New | +$37.4M |
|
12
Revolution Medicines
RVMD
$40.2B
| $30.8M | 1.72% |
670,382
| – | – |
|
13
iShares Core S&P 500 ETF
IVV
$876B
| $26.1M | 1.46% |
65,516
+844
| +1% | +$327K |
|
14
Praxis Precision Medicines
PRAX
$9.07B
| $25.5M | 1.42% |
51,901
-940
| -2% | -$668K |
|
15
Pliant Therapeutics
PLRX
$67.5M
| $22.1M | 1.24% |
562,379
| – | – |
|
16
Relay Therapeutics
RLAY
$4.02B
| $18.7M | 1.05% |
541,124
| – | – |
|
|
17
Unity
U
$12.5B
| $18.7M | 1.04% |
+186,396
| New | +$23M |
|
18
10x Genomics
TXG
$5.87B
| $16.2M | 0.9% |
+89,476
| New | +$15.5M |
|
19
Sana Biotechnology
SANA
$885M
| $15.7M | 0.88% |
+468,749
| New | +$15.3M |
|
|
KNTE
20
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $15.5M | 0.87% |
498,001
| – | – |
|
21
SPDR Gold Trust
GLD
$131B
| $15.5M | 0.86% |
96,662
+43
| +0% | +$7.23K |
|
|
GBIO
22
DELISTED
Generation Bio
GBIO
| $14.6M | 0.81% |
51,235
-911
| -2% | -$292K |
|
23
Roblox
RBLX
$34B
| $12.8M | 0.72% |
+197,642
| New | +$13.8M |
|
24
Nurix Therapeutics
NRIX
$2.43B
| $9.79M | 0.55% |
314,762
| – | – |
|
25
Vanguard FTSE Developed Markets ETF
VEA
$226B
| $8.64M | 0.48% |
175,937
+1,896
| +1% | +$92.6K |
|
Similar funds
DWT
MCC
ST
DE
SI
WIC
GC
RHJA
Harvard Management Company's Q1 2021 Portfolio in Review
As of Q1 2021, Harvard Management Company held 42 positions worth $1.79B, down 2.9% from $1.84B the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Harvard Management Company deployed $77.8M of net new capital in Q1 2021, opening 12 new positions and adding to 7 existing holdings. Its largest new stake was Intercontinental Exchange: 2,062,444 shares worth $230M.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 58% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Royalty Pharma, an estimated $189M trimmed.
- Harvard Management Company's largest Q1 2021 buy was Intercontinental Exchange: 2,062,444 shares worth $230M.
- Harvard Management Company added most to Palo Alto Networks in Q1 2021, an estimated $61.9M increase.
- Harvard Management Company's biggest Q1 2021 reduction was Royalty Pharma, cutting an estimated $189M.
- Harvard Management Company fully exited FS Development Corp. Class A Common Stock in Q1 2021, selling an estimated $2.75M.
- Harvard Management Company's ten largest holdings make up 81% of its $1.79B portfolio in Q1 2021.
- Harvard Management Company opened 12 new positions and closed 4 in Q1 2021.
- Harvard Management Company's portfolio value fell 2.9% quarter-over-quarter to $1.79B.
Based on Harvard Management Company's 13F filing for Q1 2021, filed 7 May 2021.